US FDA Talking Tough On ANDAs, Says Extensions On Complete Responses Need Justification

 
• By Derrick Gingery
  
Guidance Word In Wooden Cube
There are plenty of reasons to receive an extension to the CR response deadline, including an inability to obtain reference product samples for bioequivalence testing. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics